SRR12202462
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.590
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.470
- OXIDATIVE_PHOSPHORYLATION+0.460
- DNA_REPAIR+0.350
- PROTEIN_SECRETION+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.270
- MTORC1_SIGNALING+0.260
- SPERMATOGENESIS+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- KRAS_SIGNALING_UP-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- ANGIOGENESIS-0.380
- INFLAMMATORY_RESPONSE-0.380
- MYOGENESIS-0.370
- COAGULATION-0.360
- ALLOGRAFT_REJECTION-0.350
- INTERFERON_ALPHA_RESPONSE-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_052PZFMK | high-grade glioma | — | 0.930 |
| 2 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.923 |
| 3 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.909 |
| 4 | 004064de-0e10-491d-b3d8-bc628a8f70a8 | — | — | 0.909 |
| 5 | MNG1063 | — | — | 0.909 |
| 6 | TCGA-78-7536-01A-11R-2066-07 | — | cohortA3 | 0.906 |
| 7 | SRR5088859 | — | — | 0.905 |
| 8 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.902 |
| 9 | MBCproject_0227_T2_RNA | — | B | 0.901 |
| 10 | MDT-AP-2497 | Med | Medulloblastoma | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |